The role of HTLV in HIV-1 neurologic disease

J. R. Berger, S. Raffanti, A. Svenningsson, Micheline McCarthy, S. Snodgrass, L. Resnick

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

We performed a serologic survey for antibodies to HTLV-I/II in the course of a longitudinal study of the neurologic complications of HIV-1 infection. Nine (3.7%) of 242 HIV-1 seropositive subjects and none of 60 HIV-1 seronegative control subjects had antibodies to HTLV-I/II by ELISA. Western blot and polymerase chain reaction confirmed the presence of HTLV-I in 2 subjects and HTLV-II infection in 2 others. Both HIV-1/HTLV-I coinfected subjects and 1 HIV-1/HTLV-II coinfected subject had a slowly progressive myelopathy clinically identical to tropical spastic paraparesis/HTLV-I-associated myelopathy (TSP/HAM). The presence of a myelopathy resembling TSP/HAM in the coinfected subjects suggests that HIV-1 may enhance the expression of neurologic disease caused by HTLV. Patients with a progressive myelopathy occurring in association with HIV-1 infection should be serologically tested for the presence of HTLV. Establishing dual infection has therapeutic and prognostic import as 1 of the HIV-1/HTLV-I subjects substantially improved with corticosteroids and the HIV-1/HTLV-II subject with myelopathy had a marked improvement in the absence of therapeutic intervention.

Original languageEnglish
Pages (from-to)197-202
Number of pages6
JournalNeurology
Volume41
Issue number2
StatePublished - Feb 1 1991

Fingerprint

Nervous System Diseases
HIV-1
Human T-lymphotropic virus 2
Spinal Cord Diseases
Human T-lymphotropic virus 1
Tropical Spastic Paraparesis
HIV Infections
HTLV-II Infections
Antibodies
Nervous System
Longitudinal Studies
Adrenal Cortex Hormones
Western Blotting
Enzyme-Linked Immunosorbent Assay
Polymerase Chain Reaction
Therapeutics
Infection

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Berger, J. R., Raffanti, S., Svenningsson, A., McCarthy, M., Snodgrass, S., & Resnick, L. (1991). The role of HTLV in HIV-1 neurologic disease. Neurology, 41(2), 197-202.

The role of HTLV in HIV-1 neurologic disease. / Berger, J. R.; Raffanti, S.; Svenningsson, A.; McCarthy, Micheline; Snodgrass, S.; Resnick, L.

In: Neurology, Vol. 41, No. 2, 01.02.1991, p. 197-202.

Research output: Contribution to journalArticle

Berger, JR, Raffanti, S, Svenningsson, A, McCarthy, M, Snodgrass, S & Resnick, L 1991, 'The role of HTLV in HIV-1 neurologic disease', Neurology, vol. 41, no. 2, pp. 197-202.
Berger JR, Raffanti S, Svenningsson A, McCarthy M, Snodgrass S, Resnick L. The role of HTLV in HIV-1 neurologic disease. Neurology. 1991 Feb 1;41(2):197-202.
Berger, J. R. ; Raffanti, S. ; Svenningsson, A. ; McCarthy, Micheline ; Snodgrass, S. ; Resnick, L. / The role of HTLV in HIV-1 neurologic disease. In: Neurology. 1991 ; Vol. 41, No. 2. pp. 197-202.
@article{7b843a361dbd4f78b8ebdaec50e23129,
title = "The role of HTLV in HIV-1 neurologic disease",
abstract = "We performed a serologic survey for antibodies to HTLV-I/II in the course of a longitudinal study of the neurologic complications of HIV-1 infection. Nine (3.7{\%}) of 242 HIV-1 seropositive subjects and none of 60 HIV-1 seronegative control subjects had antibodies to HTLV-I/II by ELISA. Western blot and polymerase chain reaction confirmed the presence of HTLV-I in 2 subjects and HTLV-II infection in 2 others. Both HIV-1/HTLV-I coinfected subjects and 1 HIV-1/HTLV-II coinfected subject had a slowly progressive myelopathy clinically identical to tropical spastic paraparesis/HTLV-I-associated myelopathy (TSP/HAM). The presence of a myelopathy resembling TSP/HAM in the coinfected subjects suggests that HIV-1 may enhance the expression of neurologic disease caused by HTLV. Patients with a progressive myelopathy occurring in association with HIV-1 infection should be serologically tested for the presence of HTLV. Establishing dual infection has therapeutic and prognostic import as 1 of the HIV-1/HTLV-I subjects substantially improved with corticosteroids and the HIV-1/HTLV-II subject with myelopathy had a marked improvement in the absence of therapeutic intervention.",
author = "Berger, {J. R.} and S. Raffanti and A. Svenningsson and Micheline McCarthy and S. Snodgrass and L. Resnick",
year = "1991",
month = "2",
day = "1",
language = "English",
volume = "41",
pages = "197--202",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - The role of HTLV in HIV-1 neurologic disease

AU - Berger, J. R.

AU - Raffanti, S.

AU - Svenningsson, A.

AU - McCarthy, Micheline

AU - Snodgrass, S.

AU - Resnick, L.

PY - 1991/2/1

Y1 - 1991/2/1

N2 - We performed a serologic survey for antibodies to HTLV-I/II in the course of a longitudinal study of the neurologic complications of HIV-1 infection. Nine (3.7%) of 242 HIV-1 seropositive subjects and none of 60 HIV-1 seronegative control subjects had antibodies to HTLV-I/II by ELISA. Western blot and polymerase chain reaction confirmed the presence of HTLV-I in 2 subjects and HTLV-II infection in 2 others. Both HIV-1/HTLV-I coinfected subjects and 1 HIV-1/HTLV-II coinfected subject had a slowly progressive myelopathy clinically identical to tropical spastic paraparesis/HTLV-I-associated myelopathy (TSP/HAM). The presence of a myelopathy resembling TSP/HAM in the coinfected subjects suggests that HIV-1 may enhance the expression of neurologic disease caused by HTLV. Patients with a progressive myelopathy occurring in association with HIV-1 infection should be serologically tested for the presence of HTLV. Establishing dual infection has therapeutic and prognostic import as 1 of the HIV-1/HTLV-I subjects substantially improved with corticosteroids and the HIV-1/HTLV-II subject with myelopathy had a marked improvement in the absence of therapeutic intervention.

AB - We performed a serologic survey for antibodies to HTLV-I/II in the course of a longitudinal study of the neurologic complications of HIV-1 infection. Nine (3.7%) of 242 HIV-1 seropositive subjects and none of 60 HIV-1 seronegative control subjects had antibodies to HTLV-I/II by ELISA. Western blot and polymerase chain reaction confirmed the presence of HTLV-I in 2 subjects and HTLV-II infection in 2 others. Both HIV-1/HTLV-I coinfected subjects and 1 HIV-1/HTLV-II coinfected subject had a slowly progressive myelopathy clinically identical to tropical spastic paraparesis/HTLV-I-associated myelopathy (TSP/HAM). The presence of a myelopathy resembling TSP/HAM in the coinfected subjects suggests that HIV-1 may enhance the expression of neurologic disease caused by HTLV. Patients with a progressive myelopathy occurring in association with HIV-1 infection should be serologically tested for the presence of HTLV. Establishing dual infection has therapeutic and prognostic import as 1 of the HIV-1/HTLV-I subjects substantially improved with corticosteroids and the HIV-1/HTLV-II subject with myelopathy had a marked improvement in the absence of therapeutic intervention.

UR - http://www.scopus.com/inward/record.url?scp=0025980292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025980292&partnerID=8YFLogxK

M3 - Article

C2 - 1671529

AN - SCOPUS:0025980292

VL - 41

SP - 197

EP - 202

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 2

ER -